Heron Therapeutics (HRTX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, with the CFO and VP of Legal present; the Inspector of Elections was appointed.
The meeting was held virtually to increase access and participation, and stockholders could submit questions related to proposals.
Notice of the meeting and proxy materials were distributed to all eligible stockholders, with 188,638,866 shares outstanding and entitled to vote.
Board and executive committee updates
Seven director nominees were presented for election to serve until the 2027 annual meeting or until their successors are qualified.
Shareholder proposals
Six proposals were presented: election of directors, ratification of the independent auditor, advisory approval of executive compensation, amendments to the equity incentive and employee stock purchase plans, and ratification of the Tax Benefits Preservation Plan.
Latest events from Heron Therapeutics
- Q2 2026 net revenue was $37.7M, with guidance withdrawn amid patent and generic uncertainty.HRTX
Q2 2026 - Q1 2026 net sales $34.7M; Acute Care up, Oncology down; guidance reaffirmed.HRTX
Q1 2026 - Shareholders will vote on directors, compensation, equity plans, and tax benefit protections.HRTX
Proxy filing - Key votes include director elections, plan amendments, and auditor ratification for 2026.HRTX
Proxy filing - Shareholders will vote on directors, auditor, compensation, equity plans, and tax benefit protections.HRTX
Proxy filing - 2025 net revenue rose 7.4% to $154.9M, driven by Acute Care growth and new CMS J-Codes.HRTX
Q4 2025 - Q3 2024 featured higher sales, margin gains, and catalysts for future product expansion.HRTX
Q3 2024 - Q2 2024 sales rose to $36M, margin improved, and ZYNRELEF set for growth with VAN and NOPAIN Act.HRTX
Q2 2024 - Achieved full-year profitability and 14% revenue growth, led by ZYNRELEF and APONVIE momentum.HRTX
Q4 2024